Tribe Technology set to deliver healthy pipeline of orders from Tier-One miners. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSanofi Share News (SAN.PA)

Share Price Information for Sanofi (SAN.PA)

Euronext Paris
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 89.94
Bid: 93.35
Ask: 93.36
Change: 0.08 (0.089%)
Spread: 0.01 (0.011%)
Open: 90.23
High: 90.59
Low: 89.73
Prev. Close: 89.86
SAN.PA Live PriceLast checked at -
  • This share is an international stock.

Watchlists are a member only feature

Login to your account

European shares log weekly gains, UK's blue-chip index hits record high

Fri, 03rd Feb 2023 17:27

STOXX 600 up 0.3%, logs gains for second straight week

*

Euro zone January business activity grows -PMI

*

Sanofi falls on moderate profit growth forecast

Feb 3 (Reuters) - European shares rose on Friday, boosted by gains in healthcare and energy firms, as optimism over the outlook for the region's economy overshadowed concerns about U.S. interest rates staying elevated for longer than expected.

The pan-European STOXX 600 reversed early losses and ended up 0.3% at its highest since April last year. The index notched gains for the second straight week.

London's blue-chip FTSE 100 briefly hit a new record high on Friday, marking a potential turning point for UK assets. The index closed up 1%.

European equities rallied in the previous session on hopes that the global rate-hiking cycle was close to an end, even as the European Central Bank (ECB) stayed hawkish.

A report from the U.S. Labor Department on Friday showing

solid job additions in January

has weighed on such hopes, as a persistently tight labor market could allow the Federal Reserve to keep interest rates higher for longer.

However, analysts said the report also pointed to signs of resilience in the U.S. economy, which could alleviate some fears of a steep downturn.

In the euro zone,

business activity bounced back to growth in January, suggesting the bloc's economy might again escape a contraction this quarter and that the upturn might accelerate.

Another report showed euro zone producer prices

decelerated year-on-year

in December.

"You still have an economy holding up exceptionally well, particularly in the jobs market, and you have an earnings season that has not been so bad in Europe so far," said Giorgio Broggi, Quantitative Analyst at Moneyfarm.

"If inflation continues to stay under control in Europe and the U.S., then you expect a world where good news is good news, which means if the economy holds up, markets will do well."

Healthcare stocks led gains on the STOXX 600 on Friday, rising 1.5% on a boost from shares of large drugmakers such as Novo Nordisk and Roche Holding.

However, French drugmaker Sanofi fell 1.9% after forecasting moderate 2023 earnings growth.

Energy stocks jumped 1.0%, tracking crude prices higher as investors weighed demand recovery in top consumer China while some consumer staple stocks also lent a boost to the STOXX 600.

Dutch navigation and digital mapping company TomTom jumped 4.6% after raising its 2023 guidance.

Spain's Caixabank fell 2.7% as higher loan loss provisions overshadowed the Spanish bank's full-year results.

Casino fell 3.6% after analysts flagged that talks with Teract to combine French retail activities would not address the supermarket group's urgent need to slash debt. (Reporting by Ankika Biswas and Amruta Khandekar in Bengaluru; Editing by Savio D'Souza, Shinjini Ganguli and Mark Heinrich)

More News
13 Jun 2022 09:09

Sanofi says next-gen COVID booster shot has potential against main variants

PARIS, June 13 (Reuters) - French drugmaker Sanofi said on Monday an upgraded version of the COVID-19 vaccine candidate it is developing with GSK showed potential in two trials to protect against the virus's main variants of concern, including the Omicron BA.1 and BA.2 strains, when used as a booster shot.

Read more
10 Jun 2022 09:33

GSK closer to cracking elusive vaccine for common respiratory virus

LONDON, June 10 (Reuters) - GSK aims to get its respiratory syncytial virus (RSV) vaccine to regulators for review later this year, after interim data showed the vaccine was effective in a keenly-watched late-stage study involving older adults.

Read more
30 May 2022 17:34

European shares rise as China growth hopes boost luxury, tech stocks

May 30 (Reuters) - European shares touched their highest level in almost a month on Monday, with optimism buoyed by China's easing of COVID-19 restrictions and adding of new stimulus.

Read more
25 May 2022 11:03

French health body backs new COVID vaccine booster campaign for this autumn

PARIS, May 25 (Reuters) - France's Haute Autorite de Sante (HAS) health authority recommended preparing for a new vaccination campaign this autumn to give people aged 65 and older, and those with special health risks or conditions, access to a COVID-19 "booster" jab.

Read more
28 Apr 2022 16:17

Strong earnings spur rally across European stocks

April 28 (Reuters) - European shares moved further off six-week lows hit last session as forecast-beating results from companies including energy major TotalEnergies and automaker Volvo Car helped set aside worries about slowing global economic growth.

Read more
30 Mar 2022 09:01

What to own in uncertain times

WHAT TO OWN IN UNCERTAIN TIMES (0859 GMT)

Read more
17 Mar 2022 13:56

EMA expects data on Omicron-specific vaccine as early as April

March 17 (Reuters) - The European Medicines Agency's (EMA) leading vaccine expert on Thursday said that data on COVID-19 vaccines tailored for the Omicron variant should be available between April and the start of July, potentially paving the way for approval this summer.

Read more
17 Mar 2022 13:34

EMA expects data on Omicron-specific vaccine as early as April

March 17 (Reuters) - The European Medicines Agency's (EMA) leading vaccine expert said that data on COVID-19 vaccines tailored for the Omicron variant should be available between April and July this year, potentially paving the way for a decision by the summer.

Read more
14 Mar 2022 10:18

Sanofi shares drop on trial setback for breast cancer pill

March 14 (Reuters) - Sanofi's shares slid 5% on Monday after a drug candidate to fight a common type of breast cancer failed to slow progression of the disease in a clinical trial, knocking confidence in the French drugmaker's drug development prowess.

Read more
14 Mar 2022 09:11

Sanofi shares drop on trial setback for breast cancer pill

March 14 (Reuters) - Shares in Sanofi slumped 5.3% after an oral drug candidate to fight a common type of breast cancer that grows in response to oestrogen failed to slow progression of the disease in a clinical trial.

Read more
23 Feb 2022 15:31

Sanofi, GSK to seek approval for COVID vaccine candidate

PARIS, Feb 23 (Reuters) - French drugmaker Sanofi and its British partner GlaxoSmithKline are seeking regulatory approval for their COVID-19 vaccine to be used as a booster, as well as a standalone two-dose shot, after several setbacks.

Read more
23 Feb 2022 12:44

Sanofi, GSK to seek approval for COVID vaccine candidate

PARIS, Feb 23 (Reuters) - French drugmaker Sanofi and its British partner GlaxoSmithKline are seeking regulatory approval for their COVID-19 vaccine to be used as a booster, as well as a standalone two-dose shot, after several setbacks.

Read more
23 Feb 2022 10:22

Healthcare companies Sanofi and GSK to seek COVID-19 vaccine regulatory approval

PARIS, Feb 23 (Reuters) - Healthcare companies Sanofi and GSK said they intend to submit data from both their booster and Phase III efficacy trials as the basis for regulatory applications for a COVID-19 vaccine.

Read more
18 Feb 2022 09:00

GSK pauses trial of respiratory virus vaccine in pregnant women

Feb 18 (Reuters) - GSK has paused a late-stage trial of its vaccine candidate against the respiratory syncytial virus (RSV) in pregnant women based on safety recommendations from an independent committee, the British drugmaker said on Friday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.